<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820686</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-204</org_study_id>
    <nct_id>NCT04820686</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with&#xD;
      AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV)&#xD;
      receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial cohort of participants will be enrolled in 3 treatment groups receiving 1) VBR +&#xD;
      AB-729 + SOC NrtI, 2) VBR + SOC NrtI, or 3) AB-729 + SOC NrtI for up to 48 weeks, each&#xD;
      followed by an additional 48 weeks of SOC NrtI alone. Up to an additional 2 cohorts may be&#xD;
      added to the study in future protocol amendments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">July 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Premature Study Discontinuation</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Abnormal Laboratory Result</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serum HBsAg Below the Lower Limit of Quantitation (&lt;LLOQ)</measure>
    <time_frame>Pre-specified time points up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV Deoxyribonucleic Acid (DNA) not Detected (&lt;5 International Units/mL)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV Ribonucleic Acid (RNA) &lt;LLOQ</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean log10 HBV RNA</measure>
    <time_frame>Baseline and at pre-specified time points up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBsAg Seroconversion</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Normal Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and at pre-specified time points up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of VBR</measure>
    <time_frame>Before dosing at Baseline (Day 1) and at pre-specified time points up to 48 weeks, and at Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of AB-729</measure>
    <time_frame>2 hours after dosing at pre-specified time points up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of SOC NrtI (ETV, TDF, TAF)</measure>
    <time_frame>Before dosing at Baseline (Day 1) and at pre-specified time points up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>VBR + AB-729 + SOC NrtI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cHBV will receive VBR + AB-729 + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VBR + SOC NrtI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with cHBV will receive VBR + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks. This treatment will be used as a reference regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB-729 + SOC NrtI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with cHBV will receive AB-729 + SOC NrtI for 48 weeks followed by SOC NrtI alone for an additional 48 weeks. This treatment will be used as a reference regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBR</intervention_name>
    <description>VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).</description>
    <arm_group_label>VBR + AB-729 + SOC NrtI</arm_group_label>
    <arm_group_label>VBR + SOC NrtI</arm_group_label>
    <other_name>Vebicorvir, ABI-H0731</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-729</intervention_name>
    <description>AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.</description>
    <arm_group_label>AB-729 + SOC NrtI</arm_group_label>
    <arm_group_label>VBR + AB-729 + SOC NrtI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC NrtI</intervention_name>
    <description>Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.</description>
    <arm_group_label>AB-729 + SOC NrtI</arm_group_label>
    <arm_group_label>VBR + AB-729 + SOC NrtI</arm_group_label>
    <arm_group_label>VBR + SOC NrtI</arm_group_label>
    <other_name>Entecavir (ETV)</other_name>
    <other_name>Tenofovir disoproxil fumarate (TDF)</other_name>
    <other_name>Tenofovir alafenamide (TAF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 36 kg/m^2 and a minimum body weight of 45 kg (inclusive)&#xD;
&#xD;
          -  Female participants must be non-pregnant and have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test at Day 1&#xD;
&#xD;
          -  Chronic Hepatitis B defined as HBV infection documented for ≥6 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Hepatitis B 'e' antigen (HBeAg) negative at least 3 months prior to Screening Visit&#xD;
             (historical documentation) AND at the Screening Visit&#xD;
&#xD;
          -  Virologically suppressed on SOC NrtI therapy with nonquantifiable HBV DNA for at least&#xD;
             6 months prior to Screening&#xD;
&#xD;
          -  On a stable SOC NrtI regimen of ETV, TDF, or TAF for &gt;12 months&#xD;
&#xD;
          -  HBsAg ≥100 international units/mL at Screening&#xD;
&#xD;
          -  Lack of bridging fibrosis or cirrhosis&#xD;
&#xD;
          -  Agreement to comply with protocol-specified contraceptive requirements&#xD;
&#xD;
          -  In good general health, except for cHBV, in the opinion of the Investigator&#xD;
&#xD;
          -  Able to take oral medication and willing to receive subcutaneous injections of AB-729.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV),&#xD;
             hepatitis D virus (HDV), acute hepatitis A virus (HAV), or acute hepatitis E virus&#xD;
             (HEV)&#xD;
&#xD;
          -  Females who are lactating or wish to become pregnant during the course of the study&#xD;
&#xD;
          -  History of liver transplant or evidence of advanced liver disease, cirrhosis, or&#xD;
             hepatic decompensation at any time prior to, or at the time of Screening&#xD;
&#xD;
          -  History of persistent alcohol abuse or illicit drug abuse within 3 years prior to&#xD;
             Screening&#xD;
&#xD;
          -  Clinically significant diseases or conditions, such as cardiac disease, including&#xD;
             poorly-controlled or unstable hypertension; pulmonary disease; chronic or recurrent&#xD;
             renal or urinary tract disease; liver disease other than cHBV; endocrine disorder;&#xD;
             autoimmune disorder; poorly controlled diabetes mellitus; neuromuscular,&#xD;
             musculoskeletal, or mucocutaneous conditions requiring frequent treatment, seizure&#xD;
             disorders requiring treatment; ongoing infection or other medical conditions requiring&#xD;
             frequent medical management or pharmacologic or surgical treatment that, in the&#xD;
             opinion of the Investigator or the Sponsor, makes the subject unsuitable for study&#xD;
             participation&#xD;
&#xD;
          -  History of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  History of malignancy other than HCC unless the subject's malignancy has been in&#xD;
             complete remission off chemotherapy and without additional medical or surgical&#xD;
             interventions during the 3 years before Screening&#xD;
&#xD;
          -  History or presence at Screening of electrocardiogram (ECG) abnormalities deemed&#xD;
             clinically significant, in the opinion of the Investigator&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to any components or excipients&#xD;
             of the investigational drugs&#xD;
&#xD;
          -  History of any significant food or drug-related allergic reactions such as anaphylaxis&#xD;
             or Stevens-Johnson syndrome&#xD;
&#xD;
          -  Exclusionary laboratory results at Screening:&#xD;
&#xD;
               1. Platelet count &lt;100,000/mm^3&#xD;
&#xD;
               2. Albumin &lt;3 g/dL&#xD;
&#xD;
               3. Direct bilirubin &gt;1.2× upper limit of normal (ULN)&#xD;
&#xD;
               4. ALT ≥5× ULN&#xD;
&#xD;
               5. Serum alpha fetoprotein (AFP) ≥100 ng/mL. If AFP at Screening is &gt; ULN but &lt;100&#xD;
                  ng/mL, the subject is eligible if hepatic imaging prior to initiation of study&#xD;
                  drug reveals no lesions indicative of possible HCC&#xD;
&#xD;
               6. International Normalized Ratio (INR) &gt;1.5× ULN&#xD;
&#xD;
               7. Estimated creatinine clearance (CrCl) &lt;50 mL/min (using the Cockcroft-Gault&#xD;
                  method) based on serum creatinine and actual body weight at Screening&#xD;
&#xD;
               8. Any other laboratory abnormality deemed clinically significant by the&#xD;
                  Investigator&#xD;
&#xD;
          -  Current or prior use of prohibited (per protocol) concomitant medications from 28 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          -  Current or prior treatment for cHBV with:&#xD;
&#xD;
               -  Lamivudine, telbivudine or adefovir (any duration)&#xD;
&#xD;
               -  HBV core inhibitor (any duration)&#xD;
&#xD;
               -  siRNA or other oligonucleotide therapeutic (any duration)&#xD;
&#xD;
               -  Interferon in the 6 months prior to Screening&#xD;
&#xD;
               -  Any investigational agent for cHBV in the 6 months prior to Screening.&#xD;
&#xD;
          -  Participation in another clinical study of a drug or device whereby the last&#xD;
             investigational drug/device administration is within 60 days or 5 half-lives prior to&#xD;
             study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Assembly Biosciences</last_name>
    <phone>833-509-4583</phone>
    <email>clinicaltrials@assemblybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint George Hospital - Australia</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne Health</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Aleksandrovska</name>
      <address>
        <city>Sofia</city>
        <state>Sofia City</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment St. Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nov Rehabilitatsionen Tsentar EOOD</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Disease Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Gastroenterology Associates</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Université de Québec - Université Laval</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellington Regional Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cHBV</keyword>
  <keyword>HBV</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>vebicorvir</keyword>
  <keyword>VBR</keyword>
  <keyword>AB-729</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

